Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.50) by 12 percent. This is a 76 percent decrease over losses of $(0.25) per share from the
Benzinga · 1天前
Akebia Reports Second Quarter 2020 Financial Results
Top-line data readout of global Phase 3
PR Newswire · 1天前
Were Hedge Funds Right About Warming Up To Akebia Therapeutics Inc (AKBA)?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter
Insider Monkey · 4天前
Akebia Therapeutics to Report Second Quarter 2020 Financial Results
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report its financial results for the second quarter ended June 30, 2020 on Monday, August
PR Newswire · 08/03 12:00
Biotech Bonanza - Second Half Outlook
Seeking Alpha · 07/28 12:24
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.